Assenagon Asset Management S.A. Buys New Position in AtriCure, Inc. $ATRC

Assenagon Asset Management S.A. purchased a new stake in AtriCure, Inc. (NASDAQ:ATRC - Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 62,334 shares of the medical device company's stock, valued at approximately $1,744,000. Assenagon Asset Management S.A. owned approximately 0.12% of AtriCure at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Vanguard Group Inc. lifted its position in shares of AtriCure by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 4,903,755 shares of the medical device company's stock worth $193,993,000 after acquiring an additional 62,861 shares in the last quarter. Wellington Management Group LLP raised its holdings in shares of AtriCure by 8.1% in the 3rd quarter. Wellington Management Group LLP now owns 4,292,087 shares of the medical device company's stock valued at $151,296,000 after acquiring an additional 322,818 shares in the last quarter. First Light Asset Management LLC raised its holdings in shares of AtriCure by 32.0% in the 4th quarter. First Light Asset Management LLC now owns 1,175,445 shares of the medical device company's stock valued at $46,501,000 after acquiring an additional 285,083 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of AtriCure by 8.2% during the 1st quarter. Dimensional Fund Advisors LP now owns 997,759 shares of the medical device company's stock valued at $28,466,000 after acquiring an additional 75,862 shares during the last quarter. Finally, GW&K Investment Management LLC boosted its position in shares of AtriCure by 10.6% during the 4th quarter. GW&K Investment Management LLC now owns 952,089 shares of the medical device company's stock valued at $37,665,000 after acquiring an additional 91,054 shares during the last quarter. 99.11% of the stock is owned by hedge funds and other institutional investors.

AtriCure Price Performance

Shares of NASDAQ ATRC opened at $44.30 on Friday. The stock has a market cap of $2.25 billion, a P/E ratio of 210.96 and a beta of 1.20. AtriCure, Inc. has a twelve month low of $25.36 and a twelve month high of $44.48. The stock has a 50 day moving average of $33.91 and a two-hundred day moving average of $31.52. The company has a current ratio of 4.22, a quick ratio of 3.19 and a debt-to-equity ratio of 0.14.

AtriCure (NASDAQ:ATRC - Get Free Report) last issued its quarterly earnings data on Thursday, July 23rd. The medical device company reported $0.18 earnings per share (EPS) for the quarter. The business had revenue of $153.60 million for the quarter, compared to the consensus estimate of $151.80 million. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.During the same period in the prior year, the business earned ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. On average, research analysts forecast that AtriCure, Inc. will post 0.2 earnings per share for the current year.

Insider Activity

In other news, insider Justin J. Noznesky sold 6,182 shares of the stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $38.80, for a total transaction of $239,861.60. Following the sale, the insider directly owned 100,219 shares in the company, valued at approximately $3,888,497.20. This represents a 5.81% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Maggie Yuen sold 3,500 shares of the stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $38.42, for a total value of $134,470.00. Following the transaction, the director directly owned 14,015 shares of the company's stock, valued at approximately $538,456.30. The trade was a 19.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 47,246 shares of company stock valued at $1,777,845 over the last three months. Company insiders own 4.00% of the company's stock.

Analyst Upgrades and Downgrades

ATRC has been the subject of a number of recent research reports. Weiss Ratings raised AtriCure from a "sell (e+)" rating to a "sell (d+)" rating in a research note on Tuesday, July 28th. UBS Group decreased their price target on shares of AtriCure from $55.00 to $50.00 and set a "buy" rating on the stock in a research report on Tuesday, July 28th. Raymond James Financial set a $52.00 price objective on AtriCure in a research note on Tuesday, July 21st. Citigroup reaffirmed a "market outperform" rating on shares of AtriCure in a research report on Tuesday, July 21st. Finally, Zacks Research upgraded shares of AtriCure from a "hold" rating to a "strong-buy" rating in a report on Friday, July 24th. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, AtriCure has a consensus rating of "Moderate Buy" and a consensus target price of $48.50.

About AtriCure

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company's solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company's product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source